As DEA Rules Marijuana's Medical Status, Cannabis Giants Face RICO Claims-and Insurers Head for the Exits

Federal courts are handling allegations that large MSOs marketed recreational cannabis as medicine without conducting FDA clinical trials. Separately, MMJ’s case challenges a regulatory/enforcement approach that effectively penalized the company for following the federal drug-development pathway. The coverage points to ongoing legal and compliance risk for cannabis operators making medical claims.